Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine
A real announcement email from Novo Nordisk. Captured November 16, 2026.
Make this email yours
Migma AI designs one like it with your logo, colors, and images.

About this email
Captured Announcement
Novo Nordisk shares primary results from the phase 3 STEP Young trial evaluating semaglutide in children aged 6 to under 12 with obesity.
Traditional press release format featuring a top-left company logo, bulleted key findings, formal editorial paragraphs, and structured scientific trial data tables.
Explore similar emails
Color palette
Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.